Modelo prolab: Plan de negocios para el desarrollo de un aplicativo móvil para interconectar operaciones entre bancos: Falabella, Ripley, Alfin, de la Nación, Financieras, Cajas Municipales y Rurales de Ahorro y Crédito

El uso de la tecnología ha crecido exponencialmente en los últimos años, generando fuerte impacto en las empresas financieras, ya que, se han adaptado e innovado en servicios digitales y la experiencia del usuario. Con el rápido crecimiento de las Fintech en el país, las expectativas de los usuarios han incrementado, así como los estándares de experiencia (Ernest & Young, 2022/2023). Hoy en día los usuarios prefieren usar aplicativos móviles o páginas web para realizar diversas operaciones, para así evitar acudir a las empresas financieras, esto les permite optimizar sus tiempos y evitar la exposición a diversos riesgos (Ernest & Young, 2022/2023). No obstante, este avance tecnológico ha sido explotada por los grandes bancos del país, mientras que, la digitalización en empresas financieras con menor participación tuvo un crecimiento mínimo, afectando a los usuarios de dichas empresas. A lo largo del presente trabajo se presenta una propuesta que busca aliviar el problema en mención. Se ha dividido el trabajo en ocho capítulos, en el primero de ellos se evidencia el problema detectado. Se analiza el mercado e investiga al usuario en los capítulos dos y tres respectivamente, procediendo a exponer el proyecto de negocio y su viabilidad financiera y social, entre los capítulos cuatro al ocho. La propuesta busca darle solución al problema de los usuarios de las 35 empresas financieras que se encuentran desatendidas en lo que respecta a digitalización del sector financiero. El objetivo es brindarles a estos usuarios la posibilidad de poder integrar sus operaciones financieras mediante un aplicativo móvil que recibe por nombre “Al Toke”; esto significa que la propuesta genera un impacto social positivo al ahorrar tiempo e impacto económico, alineado con el Objetivo de Desarrollo Social (ODS) ocho “Trabajo decente y crecimiento económico”. El enfoque de la propuesta se centra en los usuarios pertenecientes a los niveles socioeconómicos (NSE) B, C y D, que sean usuarios de la Banca Múltiple (bancos), Empresas Financieras, Cajas Municipales y Rurales.The use of technology has grown exponentially in recent years having a strong impact on financial companies, which have been required to innovate their digital services with the goal to improve user experience. Furthermore, the fast growth of Fintech’s in the country has increased user expectations and experience standards. As a result, users nowadays prefer to use mobile applications or web pages to perform financial transactions to avoid a trip to the bank, save time, and/or prevent exposure to various risks. Nevertheless, while this technological progress has been achieved by Peru’s larger banks, financial entities with a smaller market share -on the contrary- have had minimal growth, leaving their users without access to the benefits of banking technologies. This thesis presents a proposal that seeks to alleviate this problem: It takes more time to users of smaller banks to perform financial transactions since, for example, they need to stop by the bank and wait. This work is divided into eight chapters, and the problem at issue is evidenced in the first one. Chapters two and three analyze the banking market and users of banking services respectively, and chapters four through eight go over our business project and its financial and social viability. This proposal seeks to solve a problem experienced by users of 35 financial companies that do not have access to the benefits offered by the digitization of the financial sector. This project aims to provide these users the possibility to integrate their financial operations through a mobile application called "Al Toke.” This platform would generate a positive impact socially by saving people time, and economically by honoring the Social Development Goal (SDG) of "Decent work and economic growth". Finally, this proposal focuses on users from socioeconomic levels B, C and D, and users of Multiple Banking (banks), Financial Companies, Municipal and Rural Savings Banks

Experiencias de aprendizaje

Libro de experiencias de aprendizaje del grupo de investigación Giteca y de los semilleros de investigación en la que se visualizan las diferentes experiencias lideradas por instructores y aprendices en las diferentes áreas y líneas de formación.Book of learning experiences of the Giteca research group and the research hotbeds in which the different experiences led by instructors and apprentices in the different areas and lines of training are visualized.Propagación in vitro como un camino de aprendizaje para la formación profesional integral -- Experiencias significativas de aprendizaje, laboratorio de hematología y parasitología animal del Complejo Tecnológico para la Gestión Agroempresarial CTPGA-SENA -- Experiencias significativas adquiridas por aprendices en el área de SENNOVA, Complejo Tecnológico para la Gestión Agroempresarial. Regional – Antioquia -- El papel de la prensa escrita en el desarrollo de la competencia textual -- Aprendiendo a Emprender con un emprendedor -- Ven y te cuento sobre ADSI -- Observaciones fenológicas del cultivo de cacao (Theobroma cacao) en los municipios de Tarazá, El Bagre y Caucasia dentro de la formación del programa SENA emprende rural -- Tejiendo sueños desde la formación -- Forraje verde hidropónico como alternativa para disminuir la expansión de la frontera agrícola en el Putumayo -- La importancia del saber hacer para ser competente en el sector agrícola -- Experiencia significativa de aprendizaje semilleros de investigación -- La investigación como ente transformador de pensamientos -- Piscícola Paraguay; Mi Sueño, Mi Proyecto de Vida! -- Estrategia de aprendizaje a través de la investigación y la empresa aplicando un programa de Responsabilidad Social Empresarial –RSE -- Matemática aplicada para procesos agroindustriales de panificaciónna85 página

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health

Risk of COVID-19 after natural infection or vaccinationResearch in context

Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health